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Abstract
Hepatic ischaemia/reperfusion (HIR) induces severe damage on hepatocyte cell membrane, which leads to hepatocyte death and the subse-
quent HIR injury. In this study, we investigated the role and the mechanism of mitsugumin-53 (MG53), a novel cell membrane repair protein, in
protecting the liver against HIR injury. Rats were subjected to sham operation or 70% warm HIR with or without recombined MG53 (rhMG53),
caudal vein-injected 2 hrs before inducing HIR. In vitro, cultured hepatocyte AML12 cells were subjected to hypoxia/reoxygenation (H/R) in the
presence of rhMG53 and/or dysferlin gene shRNAs or adenovirus transfection. HIR resulted in severe liver injury manifested as severe liver his-
tological changes and increased AST and ALT release. Post-ischaemic hepatic oxidative stress was significantly enhanced demonstrated by ele-
vated dihydroethidium level, increased 4-hydroxynonenal, enhanced 15-F2t-isoprostane and decreased SOD activity. rhMG53 administration
attenuated post-HIR liver injury, decreased liver oxidative stress and further enhanced dysferlin protein expression and its colocalization with
MG53. Similarly, H/R induced AML12 cell injury and oxidative stress, which were abolished by either rhMG53 or dysferlin overexpression but
were exacerbated by dysferlin gene knockdown. Dysferlin overexpression further increased H/R-induced increased colocalization of MG53 and
dysferlin. In conclusion, MG53 was anchored by dysferlin to reduce oxidative stress and cell death and attenuate HIR injury.
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Introduction
Ischaemia/reperfusion injury is a serious clinical complication in
many organs including the liver, heart, brain and kidney [1].
Hepatic ischaemia/reperfusion (HIR) injury mainly occurs during
liver transplantation and hepatic resection [2]. HIR by inducing
overproduction of reactive oxygen species (ROS) and superoxide
free radicals increases oxidative stress in the liver, which leads to
the destruction of hepatic cell membrane and permeability, result-
ing in hepatocyte death and the subsequent HIR injury [3]. Vari-
ous strategies targeting certain stages of pathogenesis in HIR
have been proven to alleviate the degree of injury in the liver [4].
However, none of these strategies exerts protection by directly
repairing cell membrane damage, which initiates cell/organ dam-
age during HIR.
Mitsugumin-53 (MG53), also known as TRIM72, is a member of
the tripartite motif-containing (TRIM) superfamily, which is consti-
tuted of proteins that possess a RING finger domain, one or two
B-boxes and a coiled-coil domain [9]. A series of studies identified
MG53 as an essential component of the cell membrane repair
machinery [5–8]. MG53 acts as a sensor of oxidative environment
and will subsequently be oligomerized and recruit intracellular vesi-
cles to sites of membrane disruption to form a repair patch [10].
Genetic ablation of MG53 results in defective membrane repair, and
MG53/ hearts are more susceptible to ischaemic reperfusion injury
[11]. Similarly, study has shown MG53 as a vital component of renal
protection, and targeting MG53-mediated repair of renal cells repre-
sents a potential approach to prevention and treatment of acute
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kidney injury [12]. Recent study showed that MG53 transfection
could significantly elevate MG53 protein expression in liver in vitro
[13]. However, the role of MG53 in HIR injury has not been
investigated.
In order to confer its membrane repairing effect, MG53 needs
to bind to a docking protein. Polymerase transcriptase release fac-
tor (PTRF) has been considered to be an important docking protein
that binds to MG53 at the exposed membrane lipid at the injury
site during MG53-mediated membrane repair [14]. However, PTRF
is expressed in most organs but not in the liver [15]. Dysferlin,
another docking protein, involved in repair of plasma membrane
damage, helps to recruit intracellular vesicles to site of damage in
plasma membrane, appearing to have a ubiquitous distribution
[16]. Recently, study showed dysferlin deficiency is related to ele-
vated aminotransferases which reflects the liver function [17]. Also,
the C2A domain in dysferlin has been reported to be important for
association with MG53 [18]. All these provide a clue that dysferlin
could anchor exogenous MG53 to the injury site to facilitate the
recovery of damaged cells and repair of injured cell membranes
during HIR. We, therefore, suggested that MG53 by binding to dys-
ferlin attenuates HIR-induced hepatocyte cell membrane damage,
which decreases hepatocyte death and reduces oxidative stress,
leading to the attenuation of HIR injury.
Materials and methods
Animals and hepatic warm ischaemia/
reperfusion model
Male Sprague Dawley rats (aged 6–8 weeks, weighted 180–200 g,
n = 8 per group) were obtained from SLAC Laboratory Animal Co.
Ltd (Shanghai, China). Rats were raised and breed in Vaccine Insti-
tute Laboratory in the Third Affiliated Hospital of Sun Yat-Sen Univer-
sity. After a midline laparotomy incision, an atraumatic vascular clip
was placed on the vessels blocking the portal venous and hepatic
arterial blood supply to the median and left lateral lobes of the liver,
which resulted in approximately 70% rat liver ischaemia/reperfusion
injury [19,20]. Animals in the sham groups were only received
laparotomy and vessel separation without occlusion. Some of the rats
received recombinant human MG53 protein (rhMG53, i.v., 5 mg/kg)
or vehicle (0.9% sterile saline) 2 hrs [21] before surgery. The
rhMG53 protein was obtained from Creative BioMart Company (Cat#.
TRIM72-156H). DNA sequence encoding the human MG53 (Gene ID:
493829) was fused with a polyhistidine tag at the C-terminus. The
rhMG53 protein was then expressed in Escherichia coli cells and
purified with Ni-affinity chromatography with a final purity >95% as
determined by SDS-PAGE. Animals were killed using carbon dioxide
inhalation method and samples were collected after rats were sub-
jected to partial liver ischaemia for 60 min and subsequent reperfu-
sion for 6 or 24 hrs. All animal experiments were approved by the
Animal Care and Use Committee of Sun Yat-Sen University (Guangz-
hou, China) and followed the ‘Guide for the Care and Use of Labora-
tory Animals’ (NIH Publications no. 8023, revised 1978) guidelines
for the treatment of animals.
Liver injury assay
Histology analysis was performed as described in our previous study
[22]. Serum alanine aspartate aminotransferase (ALT) and aspartate
aminotransferase (AST) levels were determined by a 7180 Biochemical
Analyzer (Hitachi, Japan).
Measurement of 15-F2t-isoprostane and
superoxide dismutase activity
15-F2t-isoprostane (Cayman, USA) level in liver tissue homogenate was
measured according to the manufacturer’s instructions via enzyme-
linked immunosorbent (ELISA) assay. The activity of superoxide dismu-
tase (SOD) was determined using a commercial kit (Nanjing Jiancheng
Bioengineering Institute, Nanjing, China) as we described [22]. SOD
activity was expressed as unit/mg wet protein.
Detection of apoptotic cell death by terminal
deoxynucleotidyl transferase dUTP nick-end
labelling
Liver tissue section terminal deoxynucleotidyl transferase dUTP nick-
end labelling (TUNEL) reaction was detected using an in situ cell death
detection kit (Roche Diagnostics GmbH, Mannheim, Germany). The sec-
tion slides were observed under a light microscope by a person who
was initially blinded to treatment groups, and ten randomly selected
fields of each slide were chosen and analysed. Finally, apoptotic index
was calculated as a percentage of apoptotic nuclei to total nuclei.
Immunohistochemical assay
The 5-lm liver paraffin-embedded sections cut from the tissue blocks
were subjected to standard procedure for dewaxing, blocking endoge-
nous peroxidase and exposing antigenic sites before immunohistochem-
ical staining. Mouse monoclonal IgG1 anti-4HNE antibody (diluted at
1:500, Abcam, USA) was used as primary antibody. Positive signal was
visualized with DAB (3,3-diaminobenzidine Dako, Denmark) colour reac-
tion. Nuclei were stained with haematoxylin. Under the code, five fields
per each slide at random choice of the viewer were semi-quantified.
Immunofluorescence
The liver paraffin blocks were cut into 5-lm sections; potential non-
specific staining in the sections was blocked with 5% bovine serum
albumin and 0.1% Triton X-100 in PBS. Mouse anti-MG53 (1:200;
Santa Cruz Biotechnology, Santa Cruz, CA, USA ) and dysferlin
(1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA ) primary anti-
bodies were used, followed by incubation with a secondary antibody
conjugated with fluorescence (1:200; Life technologies, Carlsbad, CA,
USA). Fluorescent microscope (Leica, DMLB2, Germany) was utilized
for observing the stained sections. Ten randomly selected fields of
each slide were chosen and analysed using the software ImageJ 1.48
(National Institutes of Health) according to its instructions.
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Immunoprecipitation and immunoblotting
Cultured hepatocytes or liver tissue was homogenized in lysis buffer. A
total of 500 mg extracts was subjected to immunoprecipitation with
2 mg MG53 primary antibody or IgG as negative control in the pres-
ence of 20 ml protein A/G PLUS-agarose. After extensive PBS washes,
the immunoprecipitates were denatured with 13 sodium dodecyl sul-
phate loading buffer and subjected to analysis for DYSF and MG53
expression by Western blot as described below.
Western blot analysis
The liver tissues were finely homogenized, suspended in ice-cold lysis buffer
and then centrifuged (12,000 g, 10 min) at 4°C. The homogenate super-
natants were collected for subsequent analysis. After measuring the protein
concentrations using bicinchoninic acid (BCA) method, a total 50 lg sample
was solubilized in sodium dodecyl sulphate (SDS) loading buffer and loaded
into a 10% SDS polyacrylamide gel, electrophoresed and then transferred to
a polyvinylidene difluoride (PVDF) membranes. Finally, the PVDF membranes
were incubated with dysferlin (1:1000; Santa Cruz Biotechnology), Bax, Bcl-2,
cytochrome c, caspase 3 and cleaved caspase 3 antibodies (1:1000, Cell Sig-
naling Technology, Inc, USA), followed by the corresponding secondary anti-
bodies. Protein–antibody complexes were detected with an enhanced
chemiluminescence system (KGP1125, Nanjing KeyGEN Biotech. Co., Ltd.).
Anti-GAPDH (1:500, Santa Cruz Biotechnology) was used to detect protein
levels. The density measurement was correlated to the protein levels and nor-
malized to those of GAPDH.
Cell culture and hypoxia/reoxygenation (H/R)
model
Mice hepatocyte AML12 (ATCC) was maintained following the vendors’ rec-
ommendations. Hypoxia/reoxygenation (H/R) was performed as described
in our previous study [23]. In brief, cells were incubated for 24 hrs in
Galaxy 48R hypoxia incubator (Eppendorf Company Hamburg, Germany)
with hypoxia gas mixture (5% CO2, 94% N2 and 1% O2) at 37°C. And, fol-
lowing the completion of the corresponding hypoxia time, cells were then
taken out from hypoxia incubator and transferred back to a regular incuba-
tor with 21% oxygen for 4 hrs. Cell survival was assessed using the Cell
Counting Kit-8 (CCK-8) and lactate dehydrogenase (LDH) assays.
rhMG53 delivery and DYSF shRNA and
adenovirus transfection
The rhMG53 was respectively diluted with DMEM/F12 cell culture med-
ium and added directly to the cells. After pre-treatment for 24 hrs, the
cells were transfected with or without DYSF short hairpin RNA (shRNA)
plasmid (Santa Cruz Biotechnology, Inc) or DYSF-adenovirus (Adv)
(NM_001077694, GeneCopoeia, Inc, China) for 48 hrs and then H/R
was induced as previously described [24]. Recombinant adenovirus was
generated by homologous recombination and amplified in HEK293 cells.
Transient transfections were performed with LipofectamineTM 3000
(Invitrogen, USA) according to the manufacturer’s protocol as described
in our previous study [24].
Measurement of cellular reactive oxygen species
(ROS)
Superoxide generation in liver tissue frozen section and cultured AML12
hepatocytes were estimated by the dihydroethidium (DHE) staining as
described [25]. Briefly, liver tissue frozen section or hepatocytes were
loaded with DHE (10 lM, Sigma, USA) for 30 min at 37°C. The DHE
fluorescence intensity was calculated in each of ten randomly selected
fields and analysed as a percentage relative to control by a quantitative
morphometric method.
Mitochondrial membrane potential assay
As an early event in the mitochondrial apoptosis cascade, mitochondrial
membrane potential (MMP) depolarization was measured using JC-1
assay kit (Cayman, USA). Briefly, after experimental treatment, AML12
cells were cultured in 12-well plates and incubated with JC-1 staining
solution (5 lg/ml) at 37°C for 15 min and washed twice with PBS.
MMP was estimated by measuring the fluorescence ratio of free JC-1
monomers (green) to JC-1 aggregates in mitochondria (red) using fluo-
rescence microscopy (Leica, DMLB2, Germany). Mitochondrial depolar-
ization is indicated by an elevation in the ratio of hepatocyte emitting
green fluorescence.
Statistical analysis
Data are expressed as mean  standard error of mean (SEM). Bio-
chemical assays were performed in triplicate for each specific sample.
Therefore, all the data points are means of numbers themselves result-
ing from means of triplicate measurements for these parameters.
Significance was evaluated using one-way ANOVA test (SPSS 13.0,
SPSS Inc, Chicago, IL, USA) followed by Tukey post hoc multiple com-
parisons test for unpaired values. P < 0.05 was considered statistically
significant.
Results
Liver MG53 is increased after HIR injury
As shown in Figure 1, 6 and 24 hrs after reperfusion, there were
severe histological alterations in the liver and significant increase
of Suzuki’s score (Fig. 1A and B). These changes were associ-
ated with increased AST and ALT (Fig. 1C and D), markers of
hepatic injury in the HIR group, compared with the sham group.
Interestingly, protein expression of MG53 was undetectable in the
liver in the sham group (Fig. 1E and F), while hepatic MG53 pro-
tein expression was increased at 6 hrs after reperfusion and con-
tinuously elevated even at 24 hrs after reperfusion. As MG53
was recently considered as a repaired tool, which was called
‘woundplast’ protein during cell membrane damage, whether
MG53 could repair the injured hepatocytes is still in need of
investigation.
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MG53 supplementation improves hepatic
function and ameliorates hepatocellular
oxidative stress after HIR injury
Firstly, polyhistidine-tagged MG53 (His-rhMG53) protein was identi-
fied by SDS-PAGE and Western blot. The results showed a good pur-
ity of His-rhMG53 in different protein contents (0.1, 1, 2, 4 lg;
Figure S1A). Furthermore, treatment with rhMG53 (0, 0.05, 0.10, 0.15
and 0.20 mg/ml) but not boiled rhMG53 robustly reduced LDH
release which reflected cell membrane damage in a dose-dependent
manner in hepatocytes subjected to hypoxia 24 hrs/reoxygenation
4 hrs, suggesting that rhMG53 existed normal function against cell
membrane damage (Figure S1B and C).
To test whether MG53 supplementation is effective in protecting
against HIR-induced liver injuries, a single dose of 5 mg recombined
MG53 (rhMG53) protein/kg body weight was injected via caudal vein
2 hrs before the rat was subjected to HIR injury. Control rat received
an equal volume of saline solution. As shown in Figure 2A and D,
administration of rhMG53 prior to ischaemia could effectively reduce
post-ischaemic liver histological injury, accompanied with decrease in
serum AST and ALT levels. These hepatoprotective effects of rhMG53
were observed at 6 and 24 hrs after reperfusion. Furthermore, gener-
ation of ROS and lipid peroxidation products was significantly
increased in liver demonstrated by higher levels of DHE (Fig. 2E and
F), 4-hydroxynonenal (4-HNE; Fig. 2G and H), 15-F2t-isoprostane (J)
and decreased SOD activity (I) in the HIR group than those in the
sham group at 6 and 24 hrs after reperfusion. All these changes were
reversed by rhMG53 pre-treatment.
MG53 administration prevents HIR injury through
alleviating hepatocyte apoptosis
As shown in Figure 3, post-ischaemic hepatocyte apoptosis was sig-
nificantly increased and manifested by the upsurge of TUNEL-positive
cells (Fig. 3A and C), Bax to Bcl-2 ratio, cytochrome c protein
Fig. 1 Liver MG53 expression was
increased after hepatic ischaemia/reperfu-
sion that was associated with severe liver
injury and oxidative stress. Rats were sub-
jected to HIR and samples were collected
after liver reperfusion for 6 and 24 hrs.
(A) Haematoxylin and eosin (H&E)-stained
sections of livers (9200) and Suzuki’s
scores; (B) serum aspartate aminotrans-
ferase (AST) level; (C) serum alanine
aspartate aminotransferase (ALT) level; (D
and E) immunofluorescence staining
(9400) of liver MG53 (green) and nucleus
(blue) and density analysis. Date are
mean  SEM, n = 8/group, **P < 0.01.
HIR, hepatic ischaemia/reperfusion; UD,
undetectable.
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expression and cleaved caspase 3 expression (Fig. 3B and D–F). All
these changes were prevented/reversed by rhMG53 pre-treatment
(Fig. 3). Together, these results suggest that the reduction of apop-
totic cell death contributes to MG53-mediated hepatic protection fol-
lowing HIR injury.
MG53 attenuates HIR injury via interaction with
dysferlin
We then investigated the role of dysferlin, a membrane protein
that has been considered to interact with MG53, in MG53-
mediated hepatoprotection. As shown in Figure 4A–C, hepatic
dysferlin expression was markedly increased in the HIR group
compared with that in the sham group at 6 and 24 hrs after
reperfusion. As shown in Figure 4D, co-immunoprecipitation
results showed that, in the sham group at 6 hrs after reperfusion,
there was no colocalization of MG53 and dysferlin, while after
HIR, colocalization of MG53 and dysferlin was significantly
increased. This colocalization of MG53 and dysferlin was further
enhanced after rhMG53 pre-treatment. These results indicated that
dysferlin may take an important part in rhMG53-mediated protec-
tion against HIR injury.
Down-regulation of dysferlin reversed the
protective effects of MG53 on hepatocyte H/R
damage
In order to confirm the role of MG53 in protecting the liver against
HIR injury and its interplay with dysferlin, hepatocyte AML-12 cells
were subjected to H/R stimulation with or without rhMG53 in the
presence or absence of dysferlin gene knockdown or overexpression
by corresponding shRNAs or adenovirus transfection. As shown in
Figure 5, stimulation with H/R significantly induced cell injury mani-
fested as reduced cell viability, increased LDH release and reduced
mitochondrial potential (decrease of JC-1 polymer/monomer ratio;
Fig. 5A and B, H and I), accompanied with increased oxidative stress
Fig. 2MG53 administration reduced hep-
atic injury and oxidative stress during
ischaemia/reperfusion. Rats were sub-
jected to HIR or sham operation with or
without administration of rhMG53 via cau-
dal vein and then samples were collected
after liver reperfusion for 6 and 24 hrs. (A
and B) Haematoxylin and eosin (H&E)-
stained sections of livers (9200) and
Suzuki’s scores; (C) serum aspartate
aminotransferase (AST) level; (D) serum
alanine aspartate aminotransferase (ALT)
level; (E and F) reactive oxygen species
(ROS) levels assessed using fluorescence
microscopy following the changes in
immunofluorescence staining (9200) of
liver dihydroethidium (DHE) (red). (G and
H) Immunohistochemical staining (9200)
of liver 4-hydroxynonenal (4-HNE) and
density analysis. (I) Liver antioxidant
enzyme superoxide dismutase (SOD)
activity; (J) liver oxidative stress marker
15-F2t-isoprostane level. Date are
mean  SEM, n = 8/group, **P < 0.01.
HIR, hepatic ischaemia/reperfusion;
rhMG53, recombinant human MG53 pro-
tein.
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demonstrated by increased intensity of DHE fluorescence (P < 0.01
versus control; Fig. 5F and G). All these changes were abolished or
prevented by either rhMG53 supplementation or DYSF gene overex-
pression (P < 0.01 versus H/R group), while the beneficial effects of
rhMG53 were abolished by DYSF gene knockdown. rhMG53 adminis-
tration significantly enhanced MG53 cell membrane accumulation
(P < 0.01 versus H/R group; Fig. 5D and E), accompanied with
increased colocalization of DYSF and MG53, which was further
increased by DYSF overexpression with Adv-DYSF, but was reduced
by DYSF gene knockdown (P < 0.05 versus H/R + rhMG53 group;
Fig. 5C).
Discussion
In current study, we demonstrated that MG53 supplementation, by
interacting with dysferlin, reduced hepatic oxidative stress and hepa-
tocyte death and attenuated hepatic ischaemia/reperfusion (HIR)
injury. We showed that post-ischaemic hepatic oxidative stress and
hepatocyte death were significantly increased, which was associated
with enhanced MG53 and dysferlin protein expression and their colo-
calization. We further demonstrated that supplementation of MG53,
by increasing dysferlin and its interaction, reduced hepatic oxidative
stress and attenuated hepatocyte death that eventually attenuated HIR
Fig. 3 Protective effects of rhMG53 were related to hepatic apoptosis inhibition. Rats were subjected to HIR or sham operation with or without
administration of rhMG53 via caudal vein and then samples were collected after liver reperfusion for 6 and 24 hrs. (A) Terminal deoxynucleotidyl
transferase-mediated nick-end labelling (TUNEL) staining (9200) of liver; (B) Bax/Bcl-2, caspase 3/cleaved caspase 3 and cytochrome c (Cyto-c)
protein expression; (C) percentage of TUNEL-positive cells; (D and F) density analysis of Bax/Bcl-2, caspase 3/cleaved caspase 3 and cytochrome c
(Cyto-c) protein expression. Date are mean  SEM, n = 8/group, **P < 0.01. HIR, hepatic ischaemia/reperfusion; rhMG53, recombinant human
MG53 protein.
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injury. These findings were confirmed in our in vitro model which
showed that supplementation of MG53 or dysferlin overexpression
attenuated hypoxia/reoxygenation injury in cultured AML12 cells. In
contrast, these protective effects of MG53 or dysferlin were cancelled
by dysferlin gene knockdown, indicating the importance of MG53/
dysferlin in HIR injury. To our knowledge, this is the first study inves-
tigating the protective role of MG53 in HIR injury.
The liver is sensitive to ischaemia/anoxia injury [26,27]. Ischae-
mia/reperfusion causes acute liver ischaemia/anoxia and subse-
quently a series of significant hepatic morphological changes [28].
The hepatocytes are vulnerable to ischaemia/anoxia damage [29].
Experimental evidence suggests that HIR injury is biphasic: early (2–
6 hrs after reperfusion) ischaemia/reperfusion (I/R) injury occurs
with the initiation of an inflammatory cascade involving the formation
of numerous ROS and reactive nitrogen species, and the release of
chemokines and cytokines, followed by neutrophil-mediated oxidative
stress injury occurring at 6–24 hrs of reperfusion. Oxidative stress
further damages the cell membrane and finally causes irreversible
hepatocyte injury or death between the mitochondrial inner and outer
membranes [30]. Release of cytochrome c occurs in the situation
when large amplitude mitochondrial swelling following the mitochon-
drial permeability transition causes rupture of the outer mitochondrial
membrane [31]. The change of pro-apoptotic Bcl-2 family members
such as Bax could also cause the release of cytochrome c and other
pro-apoptotic mitochondrial factors during cell apoptosis [32]. In HIR
injury, the oxidative injury to the enzyme complexes and reduction of
anti-apoptotic protein triggered apoptosis [33]. Hoglen et al. [34]
found that inhibition of caspases markedly attenuated liver damage
after HIR which suggested that apoptosis plays a critical role in HIR
injury. The apoptosis of indigenous hepatocytes leads to a generation
of AST and ALT, further demoting liver function [35]. In our rat
model, after exogenous rhMG53 administration, we observed a
significant increase of MG53 protein expression in the liver, indicating
that exogenous supplementation of MG53 is sufficient to gain liver
MG53 level. Furthermore, we showed that exogenous rhMG53 admin-
istration significantly alleviated post-HIR liver damage that was asso-
ciated with reduced hepatic oxidative stress and hepatocyte death,
suggesting that MG53-reduced HIR injury may act by decreasing
oxidative stress and cell death. We also detected the hepatic SOD
activity and reactive oxygen species generation which reflected oxida-
tive stress derived from mitochondria. More interestingly, we found
that rhMG53 treatment could also decease hepatic oxidative stress
derived from mitochondria, demonstrated as enhancement of SOD
and reduction of ROS. This finding indicates that MG53 may also play
a guardian role in mitochondrial membrane protection. These results
were consistent with the those of the previous study by Ma et al. [36]
which showed subcellular MG53 could also localize around mitochon-
dria. Nonetheless, how MG53 reduced HIR-induced oxidative stress
and hepatocyte death is still unclear.
MG53 is one of the unique muscle TRIM family proteins, and it
is previously thought to be expressed only in cardiac/skeletal mus-
cles [37]. However, recent study also showed MG53 played a role
of damage repair in other organ such as liver, kidney and the cor-
tex [12,13]. In the current study, we found that under physiological
condition, MG53 cannot be detected in the liver, while under patho-
logical condition such as HIR, MG53 is expressed in the liver, and
our results provided additional evidence that MG53 is indeed
expressed in the liver and its expression may be inducible by
stress stimulus.
MG53 was showed to modulate caveolar endocytosis in repair of
lung cells [38,39]. It is an essential component for cell membrane
injury with the repair mechanism. After membrane injury, MG53
receives the initial signal from membrane injury such as the exposure
of membrane lipid molecules [40]. Mediated by docking protein,
Fig. 4 rhMG53 attenuated hepatic ischaemia/reperfusion injury via interaction with dysferlin. Rats were subjected to HIR or sham operation with or
without administration of rhMG53 via caudal vein and then samples were collected after liver reperfusion for 6 and 24 hrs. (A and B) Immunofluo-
rescence staining (9400) of liver dysferlin (DYSF) (Red) and nucleus (blue) and density analysis; (C) Western blot assay on liver dysferlin and
MG53 at 6 hrs after reperfusion. (D) Immunoprecipitation assay of dysferlin/MG53 at 6 hrs after reperfusion. Date are mean  SEM, n = 8/group,
*P < 0.05, **P < 0.01. HIR, hepatic ischaemia/reperfusion; rhMG53, recombinant human MG53 protein.
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MG53 is then transferred to the injured membrane in cellular vesicles
and bounds to the membrane lipid molecules which were exposed
during cell damage. Subsequently, the vesicles could merge with the
cytoplasmic membrane to initiate the repair process [10]. As also
shown by previous data, acute membrane damage signals could be
detected by environmental MG53 proteins, which then recruited and
repaired the damaged cell membrane. However, MG53 could not bind
to the exposed membrane lipid molecules by itself; thus, another
mediating molecule is required at the injury site to anchor MG53 to
the exposed membrane lipid molecules [11]. Dysferlin, bands at
~230 kDa, appears to have a ubiquitous distribution and is observed
in all organ tissues tested. Skeletal muscle, kidney and heart showed
the strongest expression level; lung, stomach, spleen and liver and
uterus also showed clear labelling, with nervous tissue including
spinal cord, brain stem, cerebellum and sciatic nerve showing less
[41]. We used immunoprecipitation assays to investigate the correla-
tion between MG53 and the dysferlin protein, and we found that
MG53 is associated with dysferlin during HIR injury. HIR injury pro-
moted dysferlin accumulation at damaged hepatocyes, and in vivo
experiment showed MG53 trafficking to the damaged site requires
dysferlin. Based on immunohistochemistry, we noted that exogenous
rhMG53 was distributed in rat hepatocytes, and the histopathological
characteristics of the tissue were significantly improved compared
with the control group. Based on our immunohistochemistry results,
we noted numerous dysferlin-positive cells in the liver of the injured
group and there was no distinct difference between the injured and
control groups. Exogenous rhMG53 protein’s distribution in the liver
was consistent with the expression of dysferlin expression. All of the
above results indicate that the selective distribution and repair medi-
ated by exogenous MG53 correlates closely with dysferlin in the liver
during HIR injury.
Of note, current study proved that the cell membrane repair by
MG53 accumulation in hepatocytes during HIR is mediated by dysfer-
lin, which reduces oxidative stress and attenuates hepatocyte death in
HIR. We could not exclude the possibility that MG53 may have a
direct effect on antioxidant enzyme or anti-apoptosis factors, which
remains unknown. Moreover, whether there are other specific pro-
teins that could recruit MG53 to bind to hepatocyte cell membrane
rather than dysferlin also needs to be investigated in the future.
In conclusion, for the first time, we showed that exogenous MG53
can effectively interact with dysferlin, and thereby ameliorates hepatic
oxidative stress, attenuates hepatocyte death and eventually attenu-
ates severe hepatic ischaemia/reperfusion injury. Our data provide a
novel mechanism for protecting the liver from injury that may be
important for future treatment of hepatic ischaemia/reperfusion injury
in the clinic.
Fig. 5 Down-regulation of dysferlin reversed the protective effects of rhMG53 on hepatocyte H/R damage. (A and B) Cell proliferation was detected
by CCK-8 and cellular injury analysed by measuring LDH release in AML-12 hepatocytes after H/R stimulation; (C) immunoprecipitation assay of
dysferlin/MG53 of hepatocytes. (D) Immunofluorescence of MG53 protein expression on single hepatocyte using laser confocal microscopy
(91000); (E) density analysis of MG53 protein expression; (F and G) reactive oxygen species (ROS) levels assessed using fluorescence microscopy
following the changes in DHE fluorescence (9400); (H and I) mitochondrial membrane potential (MMP) loss measured using a JC-1 mitochondrial
membrane potential assay method (9400). Date are mean  SEM, and each experiment was performed at least independently in triplicate,
*P < 0.05, **P < 0.01. H/R, hypoxia/reoxygenation; rhMG53, recombinant human MG53 protein; DYSF, dysferlin; UD, undetectable.
Fig. 6 Schematic of proposed signalling
involved in protective effects of MG53 on
HIR injury. Hepatocyte cell membrane was
damaged by ischaemia/hypoxia and aggra-
vated by reperfusion/reoxygenation. Apop-
tosis is a main cell death pathway of
hepatocytes subjected to ischaemia/reper-
fusion or hypoxia/reoxygenation. MG53
could promote repair of damaged cell
membrane anchored by dysferlin, accom-
panied with decrease of hepatocytes
oxidative stress which was manifested by
ROS generation-caused lipid peroxidation,
DNA damage and protein peroxidation.
ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
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